Literature DB >> 29318594

Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Jia Liu1, Hermann Bihler2, Carlos M Farinha3, Nikhil T Awatade3, Ana M Romão3, Dayna Mercadante2, Yi Cheng2, Isaac Musisi2, Walailak Jantarajit1,4, Yiting Wang1, Zhiwei Cai1, Margarida D Amaral3, Martin Mense2, David N Sheppard1.   

Abstract

BACKGROUND AND
PURPOSE: Rescue of F508del-cystic fibrosis (CF) transmembrane conductance regulator (CFTR), the most common CF mutation, requires small molecules that overcome protein processing, stability and channel gating defects. Here, we investigate F508del-CFTR rescue by CFFT-004, a small molecule designed to independently correct protein processing and channel gating defects. EXPERIMENTAL APPROACH: Using CFTR-expressing recombinant cells and CF patient-derived bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating and stability with the patch-clamp and Ussing chamber techniques. KEY
RESULTS: Chronic treatment with CFFT-004 improved modestly F508del-CFTR processing, but not its plasma membrane stability. By contrast, CFFT-004 rescued F508del-CFTR channel gating better than C18, an analogue of the clinically used CFTR corrector lumacaftor. Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR channel gating. However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with a comparable mechanism of CFTR dysfunction as F508del-CFTR. To investigate the mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations. Potentiation by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the revertant mutation G550E. These data suggest that correction, but not potentiation, by CFFT-004 might involve nucleotide-binding domain 1 of CFTR. CONCLUSIONS AND IMPLICATIONS: CFFT-004 is a dual-acting small molecule with independent corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells and native airway epithelia. The limited efficacy and potency of CFFT-004 suggests that combinations of small molecules targeting different defects in F508del-CFTR might be a more effective therapeutic strategy than a single agent.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29318594      PMCID: PMC5843712          DOI: 10.1111/bph.14141

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  72 in total

1.  Domain interdependence in the biosynthetic assembly of CFTR.

Authors:  Liying Cui; Luba Aleksandrov; Xiu-Bao Chang; Yue-Xian Hou; Lihua He; Tamas Hegedus; Martina Gentzsch; Andrei Aleksandrov; William E Balch; John R Riordan
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

2.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Authors:  J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan
Journal:  Thorax       Date:  2011-08-08       Impact factor: 9.139

4.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Jeffrey H Stack; Kimberly S Straley; Caroline J Decker; Mark Miller; Jason McCartney; Eric R Olson; Jeffrey J Wine; Ray A Frizzell; Melissa Ashlock; Paul A Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-05       Impact factor: 11.205

5.  Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in murine cell line.

Authors:  K A Lansdell; Z Cai; J F Kidd; D N Sheppard
Journal:  J Physiol       Date:  2000-04-15       Impact factor: 5.182

6.  Potentiation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- currents by the chemical solvent tetrahydrofuran.

Authors:  Lauren K Hughes; Min Ju; David N Sheppard
Journal:  Mol Membr Biol       Date:  2008-09       Impact factor: 2.857

7.  VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.

Authors:  Paul D W Eckford; Mohabir Ramjeesingh; Steven Molinski; Stan Pasyk; Johanna F Dekkers; Canhui Li; Saumel Ahmadi; Wan Ip; Timothy E Chung; Kai Du; Herman Yeger; Jeffrey Beekman; Tanja Gonska; Christine E Bear
Journal:  Chem Biol       Date:  2014-04-10

8.  Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations.

Authors:  Nicoletta Pedemonte; Valeria Tomati; Elvira Sondo; Emanuela Caci; Enrico Millo; Andrea Armirotti; Gianluca Damonte; Olga Zegarra-Moran; Luis J V Galietta
Journal:  J Biol Chem       Date:  2011-03-07       Impact factor: 5.157

9.  Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.

Authors:  Nikhil T Awatade; Inna Uliyakina; Carlos M Farinha; Luka A Clarke; Karina Mendes; Amparo Solé; Juan Pastor; Maria Margarida Ramos; Margarida D Amaral
Journal:  EBioMedicine       Date:  2014-12-17       Impact factor: 8.143

Review 10.  From lab to bedside: emerging clinical applications of thymosin alpha 1.

Authors:  Allan L Goldstein; Adam L Goldstein
Journal:  Expert Opin Biol Ther       Date:  2009-05       Impact factor: 4.388

View more
  7 in total

1.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

Review 2.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 3.  Molecular basis of cystic fibrosis: from bench to bedside.

Authors:  Maria Cristina Dechecchi; Anna Tamanini; Giulio Cabrini
Journal:  Ann Transl Med       Date:  2018-09

4.  Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators.

Authors:  Onofrio Laselva; Giovanni Marzaro; Christian Vaccarin; Ilaria Lampronti; Anna Tamanini; Giuseppe Lippi; Roberto Gambari; Giulio Cabrini; Christine E Bear; Adriana Chilin; Maria C Dechecchi
Journal:  Front Pharmacol       Date:  2018-07-04       Impact factor: 5.810

5.  Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells.

Authors:  M Chioccioli; L Feriani; J Kotar; P E Bratcher; P Cicuta
Journal:  Nat Commun       Date:  2019-04-16       Impact factor: 14.919

6.  Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.

Authors:  Stella Prins; Emily Langron; Cato Hastings; Emily J Hill; Andra C Stefan; Lewis D Griffin; Paola Vergani
Journal:  J Biol Chem       Date:  2020-09-15       Impact factor: 5.157

7.  A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.

Authors:  Jyoti Sharma; Ming Du; Eric Wong; Venkateshwar Mutyam; Yao Li; Jianguo Chen; Jamie Wangen; Kari Thrasher; Lianwu Fu; Ning Peng; Liping Tang; Kaimao Liu; Bini Mathew; Robert J Bostwick; Corinne E Augelli-Szafran; Hermann Bihler; Feng Liang; Jerome Mahiou; Josef Saltz; Andras Rab; Jeong Hong; Eric J Sorscher; Eric M Mendenhall; Candice J Coppola; Kim M Keeling; Rachel Green; Martin Mense; Mark J Suto; Steven M Rowe; David M Bedwell
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.